Login | Register

Avandia (Rosiglitazone) Does Not Raise Heart Attack Risk, Study

There is not a higher risk of heart attack and cardiovascular events in patients who take controversial type 2 drug Avandia (rosiglitazone), researchers at the Duke Clinical Research Institute (DCRI) reported after carrying out a re-analysis of data from a pivotal study...

Read More

Leave a Reply

Your email address will not be published. Required fields are marked *